A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors

Sponsor
Fujian Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05938309
Collaborator
Fujian Provincial Hospital (Other), Fujian Cancer Hospital (Other), First Affiliated Hospital of Fujian Medical University (Other), 900 th Hospital of Joint Logistics Support Force (Other), The First Affiliated Hospital of Xiamen University (Other), The Second Affiliated Hospital of Fujian Medical University (Other), The First Hospital of Putian City (Other), The Affiliated Hospital(Group) of Putian University (Other), Zhangzhou Municipal Hospital of Fujian Province (Other), Longyan City First Hospital (Other)
194
1
60
3.2

Study Details

Study Description

Brief Summary

The purpose of this study is to explore the safety of laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    There is a lack of high-quality evidence on the efficacy and safety of laparoscopic resection of gastric GIST over 5cm. A multicenter, prospective cohort study was conducted to evaluate the clinical efficacy of laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors (GIST) compared to laparoscopic resection of GIST of less than 5cm. The primary evaluation parameter is overall postoperative morbidity.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    194 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Prospective, Multicenter Cohort Study on the Efficacy and Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
    Actual Study Start Date :
    May 1, 2023
    Anticipated Primary Completion Date :
    May 1, 2025
    Anticipated Study Completion Date :
    May 1, 2028

    Arms and Interventions

    Arm Intervention/Treatment
    large group

    laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors

    small group

    laparoscopic resection of less than 5cm gastric gastrointestinal stromal tumors

    Outcome Measures

    Primary Outcome Measures

    1. Overall postoperative morbidity [30 days after surgery or the first discharge ( if over 30 days hospital stay)]

      This is for the incidence of early postoperative complications, which defined as the event observed within 30 days after surgery.

    Secondary Outcome Measures

    1. intraoperative morbidity rates [1 day]

      The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.

    2. Conversion to open surgery rate [1 day]

      Conversion to open surgery rate is defined as the rate of open surgery whatever the reason

    3. Positive surgical margin rate [1 day]

      Positive surgical margin rate

    4. The variation of white blood cell count [Preoperative 7 days and postoperative 1, 3, and 5 days]

      The values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.

    5. The variation of hemoglobin [Preoperative 7 days and postoperative 1, 3, and 5 days]

      The values of hemoglobin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.

    6. The variation of C-reactive protein [Preoperative 7 days and postoperative 1, 3, and 5 days]

      The values of C-reactive protein in milligram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response

    7. overall postoperative serious morbidity rates [30 days after surgery or the first discharge ( if over 30 days hospital stay)]

      According to the Clavien-Dindo complication scoring system, grade IIIA and above is a serious complication, and when multiple complications occur at the same time, the complication with the highest grade will prevail.

    8. Time to first ambulation [30 days]

      Time to first ambulation in days is used to assess the postoperative recovery course.

    9. Time to first flatus [30 days]

      Time to first flatus in days is used to assess the postoperative recovery course.

    10. Time to first liquid diet [30 days]

      Time to first liquid diet in days is used to assess the postoperative recovery course.

    11. Time to first soft diet [30 days]

      Time to first soft diet in days is used to assess the postoperative recovery course.

    12. Duration of postoperative hospital stay [30 days]

      Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.

    13. 3-year overall survival rate [36 months]

      3-year overall survival rate

    14. 3-year disease free survival rate [36 months]

      3-year disease free survival rate

    15. 3-year recurrence pattern [36 months]

      Recurrence patterns are classified into four categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, and mixed type

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. 18 years < age < 75 years

    2. Primary gastric lesion diagnosed as gastric GSIT by endoscopic biopsy histopathology or suspected gastric GIST by preoperative endoscopy, ultrasound endoscopy, or CT or MR, and confirmed as primary gastric GIST by postoperative pathology

    3. Patient informed consent and willingness to undergo laparoscopic resection

    4. Expected laparoscopic outcome of R0 resection

    5. Performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2, Preoperative American Society of Anesthesiologists(ASA) score I-III

    Exclusion Criteria:
    1. Women during pregnancy or breast-feeding

    2. Severe mental disorder

    3. History of upper abdominal surgery (except the history of laparoscopic cholecystectomy)

    4. History of gastric surgery (except ESD/EMR for gastric cancer)

    5. History of other malignant diseases within the past five years

    6. History of unstable angina or myocardial infarction within the past six months

    7. History of a cerebrovascular accident within the past six months

    8. History of continuous systematic administration of corticosteroids within one month

    9. Requirement of simultaneous surgery for other diseases

    10. Emergency surgery due to complications (bleeding, obstruction, or perforation) caused by gastric cancer

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Gastric Surgery, Fujian Medical University Union Hospital Fuzhou Fujian China

    Sponsors and Collaborators

    • Fujian Medical University
    • Fujian Provincial Hospital
    • Fujian Cancer Hospital
    • First Affiliated Hospital of Fujian Medical University
    • 900 th Hospital of Joint Logistics Support Force
    • The First Affiliated Hospital of Xiamen University
    • The Second Affiliated Hospital of Fujian Medical University
    • The First Hospital of Putian City
    • The Affiliated Hospital(Group) of Putian University
    • Zhangzhou Municipal Hospital of Fujian Province
    • Longyan City First Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Chang-Ming Huang, Prof., Director, Head of Department of Gastric Surgery, Principal Investigator, Clinical Professor, Fujian Medical University
    ClinicalTrials.gov Identifier:
    NCT05938309
    Other Study ID Numbers:
    • FUGES-029
    First Posted:
    Jul 10, 2023
    Last Update Posted:
    Jul 10, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Chang-Ming Huang, Prof., Director, Head of Department of Gastric Surgery, Principal Investigator, Clinical Professor, Fujian Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 10, 2023